Pharmaceutical company based in Beijing, China, established in 2000 by spin-off from Thailand's Charoen Pokphand Group; manufactures large-volume injections, small-volume injections, tablets, capsules, granules, and powders. Incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange (1177).
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2000
No trial phase data available
No trial data available
No trial data available
No approval data available
- Cipla has entered an exclusive licensing and supply agreement with Sino Biopharmaceutical's subsidiary Chia Tai Tianqing (CTTQ) for the HER2 bispecific antibody-drug conjugate TQB2102 (Rolditamig Deuderuxtecan). - The deal grants Cipla exclusive development and commercialization rights across India, South Africa, and five other emerging markets, while CTTQ retains manufacturing and supply responsibilities. - TQB2102 has shown encouraging clinical potential in HER2-low advanced breast cancer and has secured three Breakthrough Therapy Designations from China's National Medical Products Administration. - The agreement strengthens Cipla's oncology pipeline with a late-stage, differentiated ADC asset without requiring early-stage drug discovery investment.
- Sino Biopharmaceutical Limited launched its new global brand, SBP Group, during its interim results meeting, with SBP standing for Science, Breakthroughs and Patients. - The rebrand reflects the company's strategic evolution from a domestic Chinese biopharmaceutical leader into a global innovator across product and business globalization. - The company has completed four out-licensing deals with multinational corporations, exceeding US$1 billion in aggregate upfront payments and over US$7 billion in total potential deal value. - Key 2026 transactions include licensing rovadicitinib to Sanofi (up to US$1.53 billion) and TQC3721 to AstraZeneca (up to US$1.9 billion).
- UOB Kay Hian maintained a Buy rating on Sino Biopharmaceutical with a price target of HK$7.20, while shares closed at HK$5.15. - Daiwa also maintained a Buy rating on the company with a price target of HK$7.00, with shares closing at HK$4.93. - Analyst consensus on Sino Biopharmaceutical stands at Strong Buy, with an average price target of HK$8.47 implying a 64.46% upside. - Corporate insider sentiment is positive, with nine insiders increasing their share purchases over the past quarter.
- Sino Biopharm's TQC2938, a humanised ST2 monoclonal antibody, demonstrated statistically significant improvement in nasal symptoms over placebo in a 136-patient Phase II trial for moderate-to-severe seasonal allergic rhinitis. - The trial enrolled patients who had inadequate response to standard intranasal corticosteroids and antihistamines, with benefits seen consistently across subgroups including those with low eosinophil counts. - TQC2938 is the first ST2-targeting biologic to show positive clinical results in allergic rhinitis, positioning it as a potential first-in-class therapy in an indication with no approved biologics in China. - The favorable safety profile comparable to placebo supports advancement into Phase III development, addressing a significant unmet need in the large low-eosinophil SAR population.
- SBP Group's subsidiary Chia Tai Tianqing Pharmaceutical has received NDA acceptance from China's CDE for M701, a CD3/EpCAM bispecific antibody targeting malignant ascites. - M701 represents China's first independently developed CD3/EpCAM bispecific antibody, designed to simultaneously target EpCAM on tumor cells and CD3 on immune T cells. - The innovative drug activates T cells to kill tumor cells by forming a bridge between tumor cells and immune T cells through dual-target binding. - This milestone follows several other regulatory achievements for SBP Group, including approvals for naldemedine, culmerciclib, and clinical trial authorization for TQB3205.
- Sino Biopharmaceutical achieved RMB 15.22 billion in innovative product sales for 2025, representing a 26.2% year-on-year increase and accounting for 47.8% of total revenue. - The company secured NMPA approval for four innovative products in 2025, including Saitanxin (Culmerciclib Capsules) and Hernexeos (Zongertinib Tablets) for oncology applications. - The company's robust pipeline includes 69 innovative drug candidates across four therapeutic areas, with nearly 20 national category 1 innovative drugs expected to receive marketing approval by 2028. - Sino Biopharm signed a major licensing deal with Sanofi for Rovadicitinib, potentially generating up to US$1.53 billion in milestone payments plus double-digit royalties.
- Sanofi has secured exclusive worldwide rights to KT501, a first-in-class trispecific T-cell engager targeting CD3, CD19, and BCMA for autoimmune diseases, with $180 million in near-term payments. - The deal includes up to $1.05 billion in development and commercial milestones plus tiered royalties, representing Kali Therapeutics' first major pharma partnership. - KT501 recently entered Phase 1a clinical trials for rheumatoid arthritis, utilizing Kali's proprietary CD3-masking platform designed to minimize cytokine release syndrome while maximizing B-cell depletion. - The partnership strengthens Sanofi's immunology pipeline as the company prepares for potential loss of Dupixent exclusivity in the early 2030s.
- Sino Biopharmaceutical's subsidiary Beijing Taihe Pharmaceutical received NMPA approval to begin clinical trials for TRD221, a first-in-class complement protein modulator for osteoarthritis treatment. - TRD221 is a complex polysaccharide injection that targets the complement system to inhibit inflammatory factors, protect cartilage cells, and potentially slow disease progression. - The drug addresses a significant unmet medical need, as current osteoarthritis treatments mainly focus on pain relief rather than disease modification. - Osteoarthritis affects 595 million patients globally as of 2020, with projections reaching 642 million by 2050, representing a substantial market opportunity.
- Sino Biopharmaceutical's subsidiary CTTQ received NMPA approval to begin clinical trials for TQB3205, a pan-KRAS inhibitor targeting advanced malignant tumors. - TQB3205 addresses a significant unmet need by targeting multiple KRAS mutation subtypes beyond G12C, potentially treating broader patient populations with KRAS-mutant cancers. - KRAS mutations are present in approximately 30% of all cancers worldwide, with high prevalence in pancreatic cancer (90%), colorectal cancer (30%-50%), and non-small cell lung cancer (15%-20%). - The approval follows the company's recent success with garsorasib, a KRAS G12C inhibitor that received NMPA marketing approval in November 2024.
- AstraZeneca's sonesitatug vedotin is set to report pivotal phase 3 data in the first half of 2026 from the global Clarity-Gastric01 trial, testing the ADC in second-line gastric cancer patients with ≥25% Claudin18.2 expression. - Two new phase 3 studies are launching in March 2025, including LaNova's tecotabart vedotin in first-line gastric cancer and FutureGen's FG-M108 monoclonal antibody in first-line pancreatic cancer. - Eight Claudin18.2-targeting ADCs are currently in phase 3 development, with companies seeking to expand beyond Astellas's Vyloy, which is only approved for patients with ≥75% Claudin18.2 expression. - Several Western pharmaceutical companies including Bristol Myers Squibb and Merck & Co have abandoned their Claudin18.2 programs, leaving the field increasingly dominated by Chinese developers.
